Navigation Links
Cardium's To Go Brands Acquired By Cell-nique And Healthy Brands Collective
Date:11/18/2013

eir business development efforts, that the company will go public, or that Cardium's preferred stock position will result in an increase in value that can be realized by Cardium; that planned product development efforts and clinical studies can be performed in an efficient and effective manner; that regulatory approvals can be obtained in a timely manner or at all; that partnering, distribution or other commercialization efforts can be achieved; that our products or proposed products will prove to be sufficiently safe and effective; that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive; that third parties on whom we depend will behave as anticipated; or that necessary regulatory approvals will be obtained.  Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development, testing and marketing of biologics, medical devices and other products, and the conduct of human clinical trials, including the timing, costs and outcomes of such trials, whether our efforts to launch new products and expand our markets will be successful or completed within the time frames contemplated, our dependence upon proprietary technology, our ability to obtain necessary funding, regulatory approvals and qualifications, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission.  We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances ari
'/>"/>
SOURCE Cardium Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Organic Waste Management Rebrands as Ennovor Biofuels to Help Customers Identify Premium Biofuel Products
2. Verenium Enters Agreement To Be Acquired By BASF
3. Cempra Provides Guidance on the Clinical Program Required for Regulatory Approval for Solithromycin for Community-Acquired Bacterial Pneumonia (CABP)
4. Cempra Presents Post-Phase 2 Analysis of Solithromycins Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP)
5. Source Scientific LLC is 100% Acquired by BIT Analytical Instruments
6. Pasteuria Bioscience to be Acquired by Syngenta
7. Camelot Healthcare Training Institute Acquired by Medtech
8. S.E.D. Labs to be Acquired by Quest Diagnostics
9. The Holistic Sanctuary Emphasizes ‘Healthy Halloween’ by Challenging Connecticut College Study that Oreos May Be as Addictive as Cocaine
10. Natural Acne Remedy, Probiotic Action Shares New Tips on Eating for Healthy Skin
11. The importance of a healthy mind & body to conceive
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, Limited ... agreement with R-Pharm, a leading Russian pharmaceutical company, to ... Russian Federation , Turkey ... States (CIS). Nemonoxacin is a novel antibiotic for the treatment ...
(Date:1/14/2014)... Jan. 14, 2014  3D Communications, a leading provider of strategic communications ... and media events in the United States ... Virginia Cox , JD, is returning to the firm,s ... re-joins 3D after more than two years of service as ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. 14, ... with two institutes from the National Institutes of Health ... bringing safer, more effective treatments to patients on a ... for Advancing Translational Sciences (NCATS) and the National Eye ...
(Date:1/14/2014)... Rockville, MD (PRWEB) January 14, 2014 ... dedicated to developing innovative information technology solutions for ... other health care stakeholders, announced today the signing ... the US Food and Drug Administration (FDA). ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... Amylin Pharmaceuticals,Inc. (Nasdaq: AMLN ) will webcast its ... on Monday, April 21, 2008 at 8:30 a.m. ET/5:30,a.m. ... will lead the call. On the same date pre-market, ... 2008., The call will be webcast live through ...
... 15 Excalibur, the new,international investment house launched ... of PIramed to Roche., (Photo: http://www.newscom.com/cgi-bin/prnh/20080415/301189 ... Roche for $185 million means a ,very substantial,cash ... fund created by Sir,Christopher five years ago., ...
... CALGARY, April 15 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,(TSX: ... by Dr. Anders,Kolb of the Nemours Center for ... for Pediatric Sarcomas" was,presented today at the American ... is being held in San Diego, California from,April ...
Cached Biology Technology:Amylin Pharmaceuticals to Webcast First Quarter Results 2Excalibur Celebrates PIramed Sale With 'Substantial Cash Return' to Investors 2Oncolytics Biotech Inc. Collaborators Present Reovirus Research for Pediatric Sarcomas at AACR Annual Meeting 2
(Date:4/24/2014)... Initial treatment for a brain infection caused by fungus could ... due to study by University of Liverpool scientists. , ... often fatal but are relatively neglected in medical research. ... Africa, Australasia and South East Asia and mainly affect people ... people a year. , The University research team has tested ...
(Date:4/24/2014)... Researchers from North Carolina State University and the University ... new ultrasound device that could help identify arterial plaque ... causing heart attack or stroke. , At issue is ... age. Some types of plaque are deemed "vulnerable," meaning ... artery wall and cause heart attack or stroke. , ...
(Date:4/24/2014)... home from Iraq and Afghanistan, post-traumatic stress disorder (PTSD) ... and the culture at-large. Estimates indicate that as many ... Afghanistan suffer from PTSD. New research from the University ... on how PTSD is linked to other diseases in ... has implications beyond the impact of the psychiatric disorder ...
Breaking Biology News(10 mins):Treatment for deadly yeast disease reduced to 3 days 2New ultrasound device may add in detecting risk for heart attack, stroke 2New study links inflammation in those with PTSD to changes in microRNA 2New study links inflammation in those with PTSD to changes in microRNA 3
... 2013 -- In January 2012, the United States Department ... make school lunches more nutritious, which included requiring schools ... either a fruit or vegetable with their purchased lunch. ... healthier lunches. In a new study scheduled for ...
... TAMPA, Florida (Feb. 21, 2013) Cardiovascular disease specialists at ... Research Institute affiliated with the University of South Florida announced ... testing a novel gene therapy for the treatment of heart ... regeneration of heart tissue by encouraging the body to deploy ...
... tissue and organ transplantation for diseases that are caused ... ethical discussions surrounding human embryonic stem cells, a lot ... (iPS cells). However, before this technique can be applied ... safety and efficacy of such iPS cells. VIB scientists ...
Cached Biology News:Smarter lunchrooms make lunch choices child's play 2New therapy for heart failure may enhance body's stem cell response at cardiovascular injury site 2New therapy for heart failure may enhance body's stem cell response at cardiovascular injury site 3Cell therapy a little more concrete thanks to VIB research 2
... purified from egg white. The extinction coefficient , ... in 10 mM phosphate-buffered saline, pH ... sodium azide and 50% glycerol. Avidin (from egg ... is purified by molecular sieving and ...
Request Info...
Request Info...
... CELLection Dynabeads (4.5 m) coated with the ... EpCAM and DNase Releasing Buffer. For ... tumour cells directly from blood, bone marrow ... enriched from bone marrow. Enriched cells are ...
Biology Products: